Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2749958 | 1.00 | TSHR (0.73) | TSHRCYP2C19MEN1CYP1A2CYP2D6 | |
| SCHEMBL7939260 | 0.87 | TSHR (0.55) | TSHRMEN1KMT2ACAPN1MAPT | |
| SCHEMBL7950760 | 0.87 | TSHR (0.55) | TSHRMEN1KMT2ACAPN1MAPT | |
| SCHEMBL7709533 | 0.85 | TSHR (0.54) | TSHRKMT2ACAPN1MAPTKDM4E | |
| SCHEMBL111475 | 0.85 | TSHR (1.00) | TSHRCYP2C19MEN1CYP1A2CYP2D6 | |
| SCHEMBL8746347 | 0.85 | TSHR (1.00) | TSHRCYP2C19MEN1CYP1A2CYP2D6 | |
| SCHEMBL3201023 | 0.85 | TSHR (1.00) | TSHRCYP2C19MEN1CYP1A2CYP2D6 | |
| SCHEMBL8875725 | 0.85 | TSHR (1.00) | TSHRCYP2C19MEN1CYP1A2CYP2D6 | |
| SCHEMBL14393160 | 0.85 | TSHR (1.00) | TSHRCYP2C19MEN1CYP1A2CYP2D6 | |
| SCHEMBL14365934 | 0.85 | TSHR (1.00) | TSHRCYP2C19MEN1CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040073045-A1 | Pyrrolidine derivative and process for producing the same | EISAI CO., LTD. (JP) | 2004-04-15 | — | — | US | disclosed |
| EP-1375479-A9 | PYRROLIDINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | Eisai Co., Ltd. (JP) | 2004-04-14 | — | — | EP | disclosed |
| EP-1375465-A1 | CYCLOOCTANONE DERIVATIVE AND CYCLODECANONE DERIVATIVE, AND USE THEREOF | Eisai Co., Ltd. (JP) | 2004-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040073045-A1 | Pyrrolidine derivative and process for producing the same | DHPS, SQLE, FDFT1 | TSHR 4497/4885CYP2C19 1775/4885MEN1 3444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.